Forte Biosciences
Yahoo Finance • 3 months ago
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its... Full story
Yahoo Finance • 3 months ago
Forte's celiac disease drug shows positive results in Phase 1b trial
DALLAS - Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biotech company with a market capitalization of $96.51 million, reported positive data from a Phase 1b trial of its lead drug candidate FB102 for celiac disease, according to... Full story
Yahoo Finance • 2 years ago
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLO... Full story
Yahoo Finance • 3 years ago
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
-Addition of Mr. David Gryska Further Strengthens Forte Board of Directors DALLAS, January 12, 2023--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to... Full story
